Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply

Vivek Subbiah, Ulrik Lassen, Eduard Gasal, Paul Burgess, Zev A Wainberg

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning

8 Citationer (Scopus)

Adgang til dokumentet

@article{0c4b66f343c34ae48c7a7efc59607310,

title = "Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply",

author = "Vivek Subbiah and Ulrik Lassen and Eduard Gasal and Paul Burgess and Wainberg, {Zev A}",

year = "2020",

month = nov,

day = "1",

doi = "10.1016/S1470-2045(20)30625-2",

language = "English",

volume = "21",

pages = "e516",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "TheLancet Publishing Group",

number = "11",

}

TY - JOUR

T1 - Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply

AU - Subbiah, Vivek

AU - Lassen, Ulrik

AU - Gasal, Eduard

AU - Burgess, Paul

AU - Wainberg, Zev A

PY - 2020/11/1

Y1 - 2020/11/1

U2 - 10.1016/S1470-2045(20)30625-2

DO - 10.1016/S1470-2045(20)30625-2

M3 - Comment/debate

SN - 1470-2045

VL - 21

SP - e516

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 11

ER -